• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cooper Companies Inc.

    3/26/26 5:42:21 PM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 12)


    Cooper Cos Inc/The

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    216648501

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    216648501


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cooper Cos Inc/The
    (b)Address of issuer's principal executive offices:

    6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, 94583
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    3/4/2026$85.00Buy → Neutral
    Rothschild & Co Redburn
    2/3/2026$100.00 → $99.00Buy
    Needham
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    10/13/2025$85.00Overweight
    Barclays
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    More analyst ratings

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00

    3/4/26 8:35:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by EVP, CFO & Treasurer Andrews Brian G

    4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)

    2/13/26 4:38:35 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form 4 filed by President & CEO White Albert G Iii

    4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)

    2/13/26 4:38:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Jay Colleen exercised 7,064 shares at a strike of $39.40, increasing direct ownership by 24% to 36,585 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    1/14/26 4:05:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market

    CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from myopia control treatments.1 The country represents approximately 12% of the global contact lens marketplace.2 MiSight® 1 day is the first soft contact lens authorized by Japan's Ministry of Health, La

    2/10/26 7:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cooper Companies Inc.

    SCHEDULE 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    3/26/26 5:42:21 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    3/6/26 4:12:10 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    3/5/26 4:27:49 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

    SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GAAP diluted EPS of $1.15, up 11%. Fiscal 2025 non-GAAP diluted EPS of $4.13, up 12%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We closed fis

    12/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care